fda glp-1 warning letters september 2025 news NCL Issues a Second Alert to Heed Warnings About Unregulated Versions of GLP -1 Weight Loss Drugs September 8, 2025: FDA launches

PlexusDx's precision-wellness approach combines genetic insights with clinical evidence to support more personalized treatment conversations, moving beyond one-size-fits-all recommendations

Some clinicians prefer to avoid the DAC version specifically because pulsatile release is more physiological

Moreover, the rising prevalence of obesity and type 2 diabetes (T2D) globally continues to significantly boost market demand, as GLP-1 agonists play an essential role in the treatment and management of these conditions

Symptoms are severe if theyre persistent and do not resolve with taking over-the-counter pain medications